granisetron has been researched along with su 11248 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baum, C; Bello, CL; Dinolfo, M; Huang, X; Levine, S; Mulay, M; Patyna, S; Rosen, L; Toh, M; Van Vugt, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for granisetron and su 11248
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for granisetron and su 11248
| Article | Year |
|---|---|
Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib.
Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Aza Compounds; Dose-Response Relationship, Drug; Electrocardiography; Fluoroquinolones; Granisetron; Heart Ventricles; Humans; Indoles; Moxifloxacin; Neoplasms; Placebos; Protein-Tyrosine Kinases; Pyrroles; Quinolines; Risk; Sunitinib; Time Factors | 2009 |